Inicial Experience in the Management of Patientes with non-Metastasic Castration Resistant Prostate Cancer.
DOI:
https://doi.org/10.54212/27068048.v8i2.35Keywords:
Non metastatic Castration, Resistant prostate Cancer, New Hormonal Agent, Enzalutamide, ApalutamideAbstract
OBJETIVE: Present the author s initial experience in handling new hormonal agents (NHA) in non-metastatic castration resistant prostate cancer. (nmCPRC).
BACKGROUND: Until a few years ago, there was no adequate treatment for the patient with non-metastatic castration resistant prostate cancer. In 2018 two new drugs were approved for treatment for this stage, after publication of clinical studies SPARTAN (apalutamide) and PROSPER (enzalutamide).
MATERIAL AND METHODS: Patients with nmCPRC are included in Unidad de Autonomía of the Instituto Guatemalteco de Seguridad Social and the private clinic Urología Integral. Included are all patients treated as from 2019.
RESULTS: 17 patients treated with Enzalutamide and 2 patientes treated with apalutamide are included, who have an average age of 77 years and 18 months in treatment with few related complications and an adequate response to it.
CONCLUSIONS: Inicial experience with Enzalutamide and Apalutamide in patients with nmCPRC is positive.
Downloads
References
Smith MR, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117 (10) 2077-85. https://doi.org/10.1002/cncr.25762 DOI: https://doi.org/10.1002/cncr.25762
Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018:378(15):1408-18. https://doi.org/10.1056/NEJMoa1715546 DOI: https://doi.org/10.1056/NEJMoa1715546
Saad F, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer(, an análisis of the Spartan trial. Lancet Oncol 2018;19(10):1404-16. https://doi.org/10.1016/S1470-2045(18)30456-X DOI: https://doi.org/10.1016/S1470-2045(18)30456-X
Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235-46. https://doi.org/10.1056/NEJMoa1815671 DOI: https://doi.org/10.1056/NEJMoa1815671
Hussain M, et al. Enzalutamide in men with nonmetastatic, castration-resitant prostate cancer. N Engl J Med 2018;378(26):2465-74. https://doi.org/10.1056/NEJMoa1800536 DOI: https://doi.org/10.1056/NEJMoa1800536
Penson DF, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer. J Clin Oncol 2016;34(18):2098-106. https://doi.org/10.1200/JCO.2015.64.9285 DOI: https://doi.org/10.1200/JCO.2015.64.9285
Smith MR et al. Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. J Urol 2003;169 2008-2012. https://doi.org/10.1097/01.ju.0000063820.94994.95 DOI: https://doi.org/10.1097/01.ju.0000063820.94994.95
Smith MR, et al. Denosumab a bone metastasis free survival in men with castration-resistant prostate cancer, results of a pase 3 randomized, placebo controlled trial. Lancet 2012; 31 3800-3806. https://doi.org/10.1016/j.yuro.2012.06.017 DOI: https://doi.org/10.1016/j.yuro.2012.06.017
H. Scher et al. Prostate Cancer Working Group. J Clin Oncol 2008 (PCWG).
Heidegger I, et al. Treantment of non-metastasic castration resistant prostate cancer in 2020. J.urolonc.2019; 1 - 8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Carlos Figueroa Lémus, Erick Stanley Petersen Juárez
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
